Sclerostin in mineralized matrices and van buchem disease

Journal of Dental Research

Volumn 88, Issue 6, 2009, Pages 569-574

  Van Bezooijen, R L ^a   Bronckers, A L ^c   Gortzak, R A ^a   Hogendoorn, P C W ^a   Van Der Wee Pals, L ^a   Balemans, W ^e   Oostenbroek, H J ^b   Van Hul, W ^e   Hamersma, H ^f   Dikkers, F G ^d   Hamdy, N A T ^a   Papapoulos, S E ^a   Lowik C W G M ^a  

^a Department of Endocrinology and Metabolic Diseases ^*  (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f Flora Clinic   (South Africa)

Author keywords

Cementocytes; Chondrocytes; Osteocytes; Sclerostin; Van buchem disease

Indexed keywords

BONE MORPHOGENETIC PROTEIN; SOST PROTEIN, HUMAN;

ADOLESCENT; ADULT; ANIMAL; ARTICLE; BIOSYNTHESIS; CARTILAGE CELL; CEMENTUM; CHILD; FEMALE; GENETIC MARKER; GROWTH PLATE; HUMAN; JAW MALFORMATION; MALE; MALOCCLUSION; METABOLISM; MIDDLE AGED; MOUSE; OSTEOCYTE; OSTEOSCLEROSIS; PANORAMIC RADIOGRAPHY; RADIOGRAPHY; TOOTH MALFORMATION;

ADOLESCENT; ADULT; ANIMALS; BONE MORPHOGENETIC PROTEINS; CHILD; CHONDROCYTES; DENTAL CEMENTUM; FEMALE; GENETIC MARKERS; GROWTH PLATE; HUMANS; JAW ABNORMALITIES; MALE; MALOCCLUSION; MICE; MIDDLE AGED; OSTEOCYTES; OSTEOSCLEROSIS; RADIOGRAPHY, PANORAMIC; TOOTH ABNORMALITIES; YOUNG ADULT;

EID: 67650761071     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/0022034509338340     Document Type: Article

References (28)

1. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et al. (2001). Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10: 537-543.
2. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, et al. (2002). Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39:91-97.
3. Balemans W, Cleiren E, Siebers U, Horst J, Van Hul W (2005). A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone 36:943-947.
4. Beighton P (1988). Sclerosteosis. J Med Genet 25:200-203.
5. Beighton P, Barnard A, Hamersma H, van der Wouden A (1984). The syndromic status of sclerosteosis and van Buchem disease. Clin Genet 25:175-181.
6. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, et al. (2005). Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583.
7. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, et al. (2001). Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577-589.
8. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, et al. (2006). Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5(G171V) to modulate Wnt activity. J Bone Miner Res 21:1738-1749.
9. Epstein S, Hamersma H, Beighton P (1979). Endocrine function in sclerosteosis. S Afr Med J 55:1105-1110.
10. Hamersma H, Gardner J, Beighton P (2003). The natural history of sclerosteosis. Clin Genet 63:192-197;
11. erratum in Clin Genet 64:176, 2004.
12. Irie K, Ejiri S, Sakakura Y, Shibui T, Yajima T (2008). Matrix mineralization as a trigger for osteocyte maturation. J Histochem Cytochem 56:561-567.
13. Leucht P, Minear S, ten Berge D, Nusse R, Helms JA (2008). Translating insights from development into regenerative medicine: the function of Wnts in bone biology. Semin Cell Dev Biol 19:434-443.
14. X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. (2005). Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887.
15. X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, et al. (2008). Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860-869.
16. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, et al. (2005). Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15:928-935.
17. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, et al. (2005). Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842-1844.
18. Semenov M, Tamai K, He X (2005). SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280:26770-26775.
19. Semenov MV, He X (2006). LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem 281:38276-38284.
20. Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, et al. (2002). A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 110:144-152.
21. Stephen LX, Hamersma H, Gardner J, Beighton P (2001). Dental and oral manifestations of sclerosteosis. Int Dent J 51:287-290.
22. Truswell AS (1958). Osteopetrosis with syndactyly; a morphological variant of Albers-Schonberg's disease. J Bone Joint Surg Br 40(B):209-218.
23. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, et al. (2004). Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814.
24. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CWGM (2005). SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319-327.
25. van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, et al. (2007). Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22:19-28.
26. rd ed. Raisz LG, Martin TJ, Bilezikian JP, editors. New York: Academic Press, pp. 139-152.
27. van Buchem FS, Hadders HN, Ubbens R (1955). An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol 44:109-120.
28. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, et al. (2003). Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267-6276.